SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
101,300
-1,300 (-1.27%)
Last updated: Apr 29, 2026, 12:00 PM KST
-1.84%
Market Cap 8.03T
Revenue (ttm) 706.74B
Net Income (ttm) 266.95B
Shares Out 78.31M
EPS (ttm) 3,408.75
PE Ratio 30.10
Forward PE 30.18
Dividend n/a
Ex-Dividend Date n/a
Volume 55,569
Average Volume 169,774
Open 102,600
Previous Close 102,600
Day's Range 101,100 - 102,600
52-Week Range 86,900 - 144,100
Beta 0.86
RSI 52.38
Earnings Date May 11, 2026

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

In 2025, SK Biopharmaceuticals's revenue was 706.74 billion, an increase of 29.06% compared to the previous year's 547.60 billion. Earnings were 266.95 billion, an increase of 10.89%.

Financial Statements

News

There is no news available yet.